Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of custirsen plus docetaxel/prednisone versus docetaxel/prednisone in metastatic castration-resistant prostate cancer
NL-OMON39174Phase 3Active, not recruiting
- Sponsor
- IQVIA Biotech
- Start
- Aug 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of custirsen in prostate cancer (PCa) (2 arms), sponsored by IQVIA Biotech. Primary endpoint: Overall survival. Started Aug 2011; status: active, not recruiting.
02
Drugs
custirsen
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON39174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39174.